Hepatocellular carcinoma with extrahepatic metastasis: Are there still candidates for transarterial chemoembolization as an initial treatment?

Jihye Kim, Dong-Hyun Sinn, Moon Seok Choi, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik

Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

* drmschoi@gmail.com

Abstract

Background and aim
Currently, sorafenib is indicated for hepatocellular carcinoma (HCC) with extrahepatic metastasis (EHM), and many other systemic agents are becoming available. However, a few HCC patients with EHM still undergo transarterial chemoembolization (TACE) for intrahepatic tumor control. We aimed to investigate whether TACE is appropriate for patients with EHM, and if so, which subgroup may benefit from TACE.

Methods
A total of 186 consecutive HCC patients (median: 55 years, male: 86.0%, hepatitis B virus: 81.7%, Child-Pugh Class A: 83.3%) with EHM (nodal metastasis: 60.8%, distant metastasis: 39.2%) between 2010 and 2014 were analyzed. Initial treatment included sorafenib in 69 patients, and TACE in 117 patients.

Results
During a median follow-up of 6.6 months (range: 0.2–94.6 months), mortality was observed in 90.3% (168/186). The median survival was better for patients who received TACE than those treated with sorafenib (8.2 months vs. 4.6 months, p < 0.001). However, baseline characteristics varied between patients initially treated with TACE and sorafenib, and the treatment modality was not an independent factor associated with overall survival (hazard ratio: 1.19, 95% confidence interval: 0.81–1.75, p = 0.36). In sub-group analysis, TACE was associated with better survival only among younger patients and those with segmental/lobar portal vein invasion.

Conclusion
In HCC patients with EHM, TACE was not an independent favorable prognostic factor compared to sorafenib. The concept of intrahepatic control in HCC patients with EHM may need
to be reevaluated in the era of promising systemic therapies, although there can be specific subgroups who still benefit from TACE.

Introduction

Primary liver cancer is the sixth most commonly diagnosed cancer, with 80% of all cases manifesting hepatocellular carcinoma (HCC), and is the second most common cause of cancer death in the world [1,2]. HCC may develop extrahepatic metastasis (EHM). Lung is the most common site of metastasis in HCC, followed by lymph nodes, bones and the adrenal glands [3]. Currently, systemic agents such as sorafenib are available for the treatment of HCC patients with EHM [4,5], and can prolong survival of HCC patients [6]. However, in a subset analysis of the phase III sorafenib Asia-Pacific trial, sorafenib was associated with only modest improvement of median overall survival compared with placebo in patients with lung metastasis (5.6 versus 4.2 months), and the difference was not statistically significant [hazard ratio (HR): 0.87, 95% confidence interval (CI): 0.56, 1.37]. Similar results were found in patients with lymph node metastasis (overall survival, 5.6 versus 3.2 months, HR: 0.64, 95% CI: 0.38, 1.08) [7]. Moreover, only a minor proportion of HCC patients die from EHM, while most patients die of intrahepatic HCC progression or liver failure [8–10]. The controllability of intrahepatic lesions was identified as an important prognostic factor for survival in HCC patients with EHM [11]. Hence, in real-life practice, some patients with HCC and EHM have been treated for intrahepatic HCC using locoregional treatments, usually transarterial chemoembolization (TACE) [12–15], without robust evidence to support. Moreover, these data were derived from an era when sorafenib and other immunotherapeutic agents were not widely available.

The purpose of this study was to determine whether TACE was associated with improved survival compared with sorafenib in HCC patients with EHM and to identify possible subgroups of HCC patients with EHM who may benefit from TACE.

Materials and methods

Study design and patient selection

This single-center, retrospective cohort study was conducted using a prospectively collected HCC registry at the Samsung Medical Center, Seoul, Korea between 2010 and 2014. The HCC registry of Samsung Medical Center is a prospective registry that records baseline clinical characteristics, tumor variables, and the initial treatment modalities of every newly-diagnosed HCC patient aged 18 years or older who received care at the Samsung Medical Center. A diagnosis of HCC was established either histologically or clinically according to the regional HCC guideline [16,17]. We screened a total of 261 HCC patients with EHM at diagnosis. Among them, we included a total of 186 consecutive newly diagnosed HCC patients with EHM who received TACE or sorafenib as an initial treatment, by excluding patients who received supportive care only (n = 44) or who underwent resection, radiofrequency ablation or radiation therapy as an initial treatment (n = 31). The study was approved by the Ethics Committee of Samsung Medical Center and was conducted in accordance with the principles of the Declaration of Helsinki. Because this study was based on a retrospective analysis of existing administrative and clinical data, the requirement for informed patient consent was waived by the Institutional Review Board.
Treatment and follow-up

In principle, sorafenib was started at a dose of 400 mg twice daily (800 mg/day). The patients were usually treated with the initial dose during the first 2 weeks, continued every 4 weeks if there were no side effects. Dose reduction or temporary interruption of sorafenib followed any significant drug-related adverse events. If the patient tolerated sorafenib, the therapy was continued until disease progression [6].

Conventional TACE was performed with an intra-arterial injection of a mixture of doxorubicin hydrochloride (Adriamycin; Dong-A Pharm, Seoul, Republic of Korea) and iodized oil (Lipiodol; Laboratoire Andre Guerbet, Aulnay-sous-Bois, France) following a femoral approach, celiac angiogram and superselection of tumor feeder at the level of the segmental or subsegmental artery with a micro-guidewire and a 2.0-Fr microcatheter. The feeder(s) were embolized with gelatin sponge pledges (Cutanplast, MasciaBrunelli S.P.A, Milano, Italy) until hemostasis was achieved [18]. Contrast–enhanced computed tomography (CT) or magnetic resonance (MR) imaging was performed at baseline and every 2–4 months.

Variables and data collection

We categorized patients according to initial treatment modality: sorafenib or TACE. We used the following variables obtained from the HCC registry by trained abstractors: age at diagnosis, sex, etiology of HCC, Eastern Cooperative Oncology Group (ECOG) performance status, Child-Pugh Class, serum albumin and bilirubin levels, albumin-bilirubin (ALBI) grade, serum alpha-fetoprotein (AFP), tumor characteristics (e.g., number of tumors, tumor type, maximal tumor diameter, portal vein invasion, and bile duct invasion), mUICC stage, BCLC stage, and initial treatment modality. In this study, we additionally determined the location of extrahepatic spread by reviewing the imaging findings and electronic medical records, as the HCC registry lacked the detailed information. Tumor type was classified as either nodular or diffuse. The nodular tumor type comprised single to multiple discrete intrahepatic tumors whereas the diffuse tumor type represented huge tumor (at least 7 cm in diameter) with ill-defined edges [19]. Overall survival was defined as the time from diagnosis to the last follow-up or death, whichever occurred first. The referral date was May 31, 2018.

Statistical analysis

All statistical analyses were conducted using SPSS 24 software package (IBM Corporation, Armonk, NC, USA). Data are expressed as the median (quartile), median (range), or number (%) of patients. The chi-square test, Fisher’s exact test, and Mann-Whitney test were used to compare the baseline characteristics and variables between the two groups. Survival analyses were performed using the Kaplan-Meier method with the differences in survival curves assessed using the log-rank test. Cox proportional hazards models were used to estimate the hazard ratios (HRs) for the variables. Any significant risk factors associated with overall survival were used in the stratified analysis comparing TACE and sorafenib. All analyses involved two-sided tests of significance with a P value less than 0.05 considered as statistically significant.

Results

Table 1 shows the baseline characteristics of the study population and comparison based on the initial treatment modality. One hundred seventeen patients (62.9%) received TACE, and 69 patients (37.1%) underwent the initial treatment with sorafenib. Patients treated with sorafenib were younger, with higher AFP levels, higher proportion of diffuse/infiltrative tumor,
Table 1. Baseline characteristics and comparison based on initial treatment modality.

| Variables                  | Overall (N = 186) | TACE (N = 117) | Sorafenib (N = 69) | p value |
|----------------------------|-------------------|----------------|-------------------|---------|
| Age                        | 55 (49–63)        | 57 (51–65)     | 54 (48–59)        | 0.014   |
| Male                       | 160 (86.0)        | 100 (85.5)     | 60 (87.0)         | 0.83    |
| Etiology                   |                   |                |                   | 0.33    |
| HBV*                       | 152 (81.7)        | 93 (79.5)      | 59 (85.5)         |         |
| Others†                    | 34 (18.3)         | 24 (20.5)      | 10 (14.5)         |         |
| Performance status (ECOG)  |                   |                |                   | 0.15    |
| 0                          | 165 (88.7)        | 107 (91.5)     | 58 (84.1)         |         |
| ≥1                         | 21 (11.3)         | 10 (8.5)       | 11 (15.9)         |         |
| Child-Pugh class           |                   |                |                   | 0.52    |
| A                          | 155 (83.3)        | 100 (85.5)     | 55 (79.7)         |         |
| B                          | 28 (15.1)         | 15 (12.8)      | 13 (18.8)         |         |
| C                          | 3 (1.6)           | 2 (1.7)        | 1 (1.4)           |         |
| ALBI grade                 |                   |                |                   | 0.33    |
| 1                          | 72 (38.7)         | 50 (42.7)      | 22 (31.9)         |         |
| 2                          | 195 (56.5)        | 62 (53.0)      | 43 (62.3)         |         |
| 3                          | 9 (4.8)           | 5 (4.3)        | 4 (5.8)           |         |
| AFP, ng/ml                 | 569 (33–13883)    | 252 (18–3837)  | 5655 (88–48595)   | <0.001  |
| <20                        | 42 (22.6)         | 31 (26.5)      | 11 (15.9)         | 0.11    |
| ≥20                        | 144 (77.4)        | 86 (73.5)      | 58 (84.1)         |         |
| Tumor type                 |                   |                |                   | 0.015   |
| Nodular                    | 156 (83.9)        | 104 (88.9)     | 52 (75.4)         |         |
| Diffuse / infiltrative     | 30 (16.1)         | 13 (11.1)      | 17 (24.6)         |         |
| Maximal tumor diameter     |                   |                |                   | 0.94    |
| <5 cm                      | 41 (22.0)         | 26 (22.2)      | 15 (21.7)         |         |
| ≥5 cm                      | 145 (78.0)        | 91 (77.8)      | 54 (78.3)         |         |
| Portal vein invasion       |                   |                |                   | 0.042   |
| No                         | 69 (37.1)         | 47 (40.2)      | 22 (31.9)         |         |
| Segmental/lobar            | 83 (44.6)         | 55 (47.0)      | 28 (40.6)         |         |
| Main/bilateral             | 34 (18.3)         | 15 (12.8)      | 19 (27.5)         |         |
| Bile duct invasion         | 17 (9.1)          | 9 (7.7)        | 8 (11.6)          | 0.43    |
| LN metastasis              |                   |                |                   | 0.015   |
| No                         | 48 (25.8)         | 23 (19.7)      | 25 (36.2)         |         |
| Yes                        | 138 (74.2)        | 94 (80.3)      | 44 (63.8)         |         |
| Distant metastasis         |                   |                |                   | <0.001  |
| Lung                       | 51 (27.3)         | 16 (13.6)      | 35 (50.7)         |         |
| Bone                       | 14 (7.5)          | 7 (5.9)        | 7 (10.1)          |         |
| Adrenal gland              | 7 (3.7)           | 2 (1.7)        | 5 (7.2)           |         |
| Others†                    | 5 (2.7)           | 5 (4.2)        | 0 (0)             |         |
| Type of EHM                |                   |                |                   | <0.001  |
| LN                         | 113 (60.8)        | 90 (76.9)      | 23 (33.3)         |         |
| Distant + LN metastases    | 25 (13.4)         | 4 (3.4)        | 21 (30.4)         |         |

(Continued)
more advanced portal vein invasion, and distant metastasis when compared with those that received TACE (Table 1).

Initial and subsequent treatment are summarized in Table 2. Of the 117 patients who underwent TACE, median number of TACE sessions were two. Twelve patients showed hepatic decompensation, defined by new-onset hyperbilirubinemia (>3 mg/dl) which was attributable to TACE. Three of them had significant hepatic dysfunction preventing further treatment, while the other nine patients recovered within an average of one week (range 3 to 21 days) of supportive care. Of the 69 patients who started sorafenib, median duration of sorafenib treatment was 1.5 months (range: 0.1–75.8 months), and 21 patients (30.4%) had dose reduction/interruption or permanent discontinuation related to sorafenib side effects. After initial treatment, sorafenib was used as a subsequent treatment in 26 patients (22.2%) among those who started treatment with TACE, while two patients (2.9%) received TACE among those who started treatment with sorafenib (Table 2).

Table 1. (Continued)

| Variables                  | Overall (N = 186) | TACE (N = 117) | Sorafenib (N = 69) | p value |
|----------------------------|------------------|---------------|--------------------|---------|
| Distant metastasis only    | 48 (25.8)        | 23 (19.7)     | 25 (36.2)          |         |

Data are presented as number (%) or median (quartile)
†One case in systemic therapy group had both HBV and HCV.
‡Others include alcohol and non-B non-C.
§Others include peritoneum, kidney, brain and rectovesical seeding.
Abbreviation: TACE, transarterial chemoembolization; Eastern Cooperative Oncology Group, ECOG; ALBI, albumin-bilirubin; AFP, alpha-fetoprotein; EHM, extrahepatic metastasis; LN, lymph node

https://doi.org/10.1371/journal.pone.0213547.t001

Table 2. Initial and subsequent treatment according to initial treatment modality.

|                         | TACE (n = 117) | Sorafenib (n = 69) |
|-------------------------|---------------|--------------------|
| Number of total TACE sessions | 2 (1–15)      | N/A                |
| One time                | 38 (32.5%)    | N/A                |
| Two times               | 23 (19.6%)    | N/A                |
| Three or more times     | 56 (47.9%)    | N/A                |
| Interval between TACE sessions (months) | 1.4 (0.4–10) | N/A                |
| Hepatic decompensation after TACE† | 12 (10.2%)   |                    |
| Recovered after supportive care | 9 (7.7%)     |                    |
| Not recovered after TACE | 3 (2.6%)      |                    |
| Median duration of sorafenib use (months) | 1.5 (0.1–75.8) |                |
| Dose reduction/interruption | 14 (20.3%)  |                    |
| Permanent discontinuation | 7 (10.1%)   |                    |
| Other subsequent treatments |            |                    |
| Sorafenib               | 26 (22.2%)    | N/A                |
| TACE                    | N/A           | 2 (2.9%)           |
| Radiotherapy            | 47 (40.2%)    | 4 (5.8%)           |
| Others*                 | 3 (2.6%)      | 4 (5.8%)           |

Data is expressed as median (range) or number (%). Abbreviation. TACE, transarterial chemoembolization; N/A, not applicable.
*Other treatment includes radiofrequency ablation, combination treatment with radiofrequency ablation and TACE, transarterial radioembolization, and clinical trials.
†Defined by new-onset hyperbilirubinemia (>3 mg/dl) after TACE session.

https://doi.org/10.1371/journal.pone.0213547.t002
During a median follow-up of 6.7 months (range: 0.2–94.6 months), mortality was observed in 168 patients (90.3%). Age, etiology, ALBI grade, AFP level, tumor type, portal vein invasion, type of EHM, and initial treatment modality were factors associated with overall survival in univariate analysis (Table 3). Median survival was higher in patients treated with TACE rather than sorafenib (8.2 months vs. 4.6 months, \( p < 0.001 \), Fig 1). However, in multivariable adjusted analysis, treatment modality was no longer an independent risk factor for overall survival (hazard ratio (HR): 1.19, 95% confidence interval (CI): 0.81–1.75, \( p = 0.36 \)) (Table 3). The ALBI grade, portal vein invasion, and type of extrahepatic spread were independent factors associated with overall survival (Table 3).

In subgroup analysis, TACE was associated with better overall survival than sorafenib in patients at a younger age, with HBV infection, higher AFP level, nodular tumor type, ALBI grade 2 to 3, segmental/lobar portal vein invasion, or nodal metastasis in un-adjusted analysis (Table 4). However, in multivariable adjusted model, TACE was associated with better survival than sorafenib, only for patients aged below 60 years, and patients with segmental/lobar portal vein invasion.

**Discussion**

In this study, we analyzed a total of 186 consecutive HCC patients with EHM who were treated initially with TACE (\( n = 117 \)) or sorafenib (\( n = 69 \)) at a single tertiary hospital. Patients treated with TACE showed better overall survival compared with those receiving sorafenib. However, baseline characteristics varied significantly, and when adjusted, no significant difference
Fig 1. Overall survival according to initial treatment modality in hepatocellular carcinoma patients with extrahepatic spread. Abbreviation: TACE, transarterial chemoembolization.

https://doi.org/10.1371/journal.pone.0213547.g001

existed in overall survival between TACE- or sorafenib-treated patients. In subgroup analysis, TACE was associated with better overall survival than sorafenib among younger patients (age < 60 years) and in patients with segmental/lobar portal vein invasion. Among the other subgroups, TACE was not a factor linked to improved overall survival.

To the best of our knowledge, no randomized controlled trials have investigated the efficacy and safety of TACE compared with those of sorafenib in HCC patients with EHM. Several observational studies are available, but with limitations. In a study involving 251 newly diagnosed HCC patients with EHM, repeated TACE showed survival benefit [14]; however, only a minor proportion received sorafenib treatment (n = 13). Another study involving 240 patients with HCC found intrahepatic tumor status as a significant predictor of survival [20]; however, it was composed of a heterogeneous population (141 patients with EHM at diagnosis and 99 patients who developed EHM during follow-up) who underwent a variety of treatment. Another study from Germany analyzed 215 patients with metastatic HCC and reported that treatment with intrahepatic TACE (n = 42) and a combination of TACE and sorafenib (n = 23) were associated with improved survival [15]. However, the reference group comprised those without therapy (n = 102), and not those that received sorafenib (n = 48) as initial treatment. In a study conducted at three German referral centers, TACE (n = 74) was not associated with better survival than sorafenib (n = 98) among HCC patients with EHM [21]. Several studies compared TACE and sorafenib in advanced-stage HCC [22–26] and reported different results. In these studies, the advanced stage was usually defined by BCLC stage C, including patients with or without EHM. In a study involving 382 advanced-stage HCC treated with TACE, those with EHM showed significantly worse survival compared with those without EHM, suggesting the presence of EHM means aggressive tumor biology [22]. Hence, studies comparing TACE and sorafenib in advanced-stage HCC should be carefully interpreted based on the presence of EHM.

In our study, survival was better in the TACE group; however the benefit disappeared after multivariable adjustment for age, etiology, ALBI grade, AFP level, tumor type, portal vein invasion, and type of EHM. This finding indicates that the better outcome observed in patients
who received TACE was due to the selection of better patients upfront. Since it is widely accepted that liver function and tumor status have a strong influence on the prognosis of patients with HCC, it is important to preserve liver function [27–29]. In our study, the ALBI grade 2 or higher was associated with a significantly lower survival rate than the ALBI grade 1 (HR 1.54, 95% CI: 1.10–2.15, p = 0.011). Repeated exposure to TACE increases the risk of liver dysfunction [30]. In our series, 10.2% of patients experienced hepatic decompensation after TACE, and of those, three patients (2.6%) did not recover after TACE. Therefore, repeated TACE for HCC patients with EHM without strong evidence of the appropriate target group can lead to worse patient survival in this era of development of promising new systemic drugs. To determine whether the specific subgroups exist who may benefit from TACE, we performed a subgroup analysis. The analysis revealed that younger age (< 60 years) and portal vein invasion limited to segmental/lobar invasion showed favorable outcome following TACE compared with sorafenib. However, careful interpretation is needed as the definitive factors underlying the enhanced outcome in this subgroup are not clear. In a recent randomized controlled trial for advanced-stage HCC defined by macroscopic vascular invasion, TACE combined with radiotherapy showed better outcome than sorafenib [31], indicating that HCC with portal vein invasion may be ameliorated with TACE compared with sorafenib; however, in this trial, patients with EHM was excluded from the beginning [31]. In this study, the median duration of sorafenib use was 1.5 months. Sorafenib dose reduction, interruption or permanent discontinuation was observed in 30.4% of patients. Among patients who started

| Variables | Un-adjusted | p value | Multivariable-adjusted | p value |
|-----------|-------------|---------|------------------------|---------|
| Age       |             |         |                        |         |
| <60 (n = 126) | 0.46 (0.32–0.68) | <0.001 | 0.58 (0.37–0.91) | 0.017  |
| ≥60 (n = 60)  | 0.95 (0.51–1.77) | 0.88   | 1.99 (0.91–4.38) | 0.086  |
| Etiology   |             |         |                        |         |
| HBV (n = 152) | 0.61 (0.43–0.85) | 0.004 | 0.74 (0.49–1.12) | 0.15   |
| Others (n = 34) | 0.51 (0.23–1.14) | 0.10   | 2.27 (0.73–7.12) | 0.16   |
| AFP        |             |         |                        |         |
| <20 ng/ml (n = 42) | 0.78 (0.37–1.64) | 0.52   | 1.52 (0.54–4.25) | 0.43   |
| ≥20 ng/ml (n = 144) | 0.54 (0.38–0.76) | <0.001 | 0.75 (0.49–1.16) | 0.20   |
| Tumor type |             |         |                        |         |
| Nodular (n = 156) | 0.58 (0.41–0.82) | 0.002 | 0.78 (0.53–1.17) | 0.23   |
| Diffuse (n = 30)  | 0.99 (0.46–2.13) | 0.98   | 2.93 (0.69–12.43) | 0.15   |
| ALBI grade |             |         |                        |         |
| 1 (n = 72) | 0.61 (0.36–1.05) | 0.076 | 0.92 (0.47–1.75) | 0.79   |
| 2 to 3 (n = 114) | 0.55 (0.37–0.82) | 0.003 | 0.81 (0.48–1.33) | 0.40   |
| Portal vein invasion |             |         |                        |         |
| No (n = 69)  | 0.67 (0.39–1.15) | 0.15   | 1.51 (0.78–2.91) | 0.21   |
| Segmental/lobar (n = 83) | 0.49 (0.30–0.80) | 0.004 | 0.44 (0.25–0.79) | 0.006  |
| Main/bilateral (n = 34) | 0.50 (0.24–1.05) | 0.067 | 0.76 (0.27–2.15) | 0.61   |
| Type of extrahepatic spread |             |         |                        |         |
| LN (n = 113) | 0.58 (0.36–0.94) | 0.028 | 0.70 (0.41–1.19) | 0.19   |
| Distant metastasis ± LN (n = 73) | 0.82 (0.51–1.34) | 0.44 | 1.01 (0.57–1.77) | 0.98   |

Abbreviation: AFP, alpha-fetoprotein; ALBI, albumin-bilirubin; LN, lymph node

https://doi.org/10.1371/journal.pone.0213547.t004
treatment with TACE, 22.2% received subsequent treatment with sorafenib, while subsequent TACE treatment was observed in only 2 patients who started treatment with sorafenib. The subsequent treatment with sorafenib may have also had favorable effects on patient outcome among patients who started treatment with TACE. Taken together, performing TACE for intrahepatic tumor control in EHM does not appear to be an effective strategy in the era of sorafenib. Although it seems that TACE might be superior in certain patient subgroups, such as those younger and with segmental or lobar portal vein invasion, additional studies are warranted. In the future, with better systemic management options, the concept of intrahepatic tumor control in HCC patients with extrahepatic metastasis may require re-evaluation.

There are some limitations of this study. This is an observational study of patients treated according to physician’s direction, with possible unidentifiable bias favoring or excluding each treatment. In our series, majority of patients (76.9%) who underwent TACE had LN only metastasis, while LN only metastasis was observed in only 33.3% of patients who started sorafenib. The extent of intrahepatic or extrahepatic tumor control and the changes in liver function during treatment were not evaluated. This study was confined to a single referral center in a HBV-endemic area, limiting generalizability given the diverse etiology of HCC.

In summary, although the overall survival was better in HCC patients with EHM who received TACE compared with sorafenib, TACE was not associated with improved outcome in the multivariable adjusted model, suggesting that better outcomes were attributed to selection bias based on differences in baseline characteristics, and not from TACE. Although there can be specific subgroups who may benefit from TACE over sorafenib such as those younger and with segmental or lobar portal vein invasion, prospective well-designed studies are needed to confirm this finding. In the future, with the development and availability of more promising systemic agents, the concept of intrahepatic tumor control using TACE in HCC patients with EHM may no longer be necessary.

Author Contributions
Conceptualization: Dong-Hyun Sinn, Moon Seok Choi.
Data curation: Jihye Kim.
Formal analysis: Jihye Kim.
Investigation: Jihye Kim.
Methodology: Jihye Kim, Dong-Hyun Sinn.
Resources: Dong-Hyun Sinn, Moon Seok Choi, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik.
Supervision: Seung Woon Paik.
Visualization: Wonseok Kang.
Writing – original draft: Jihye Kim.
Writing – review & editing: Jihye Kim, Moon Seok Choi.

References
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136:E359–86. https://doi.org/10.1002/ijc.29210 PMID: 25220842
2. McGlynn KA, Patrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis. 2015; 19:223–38. https://doi.org/10.1016/j.cld.2015.01.001 PMID: 25921660

3. Katyal S, Oliver JH 3rd, Peterson MS, Ferris JV, Carr BS, Baron RL. Extracapsular metastases of hepatocellular carcinoma. Radiology. 2000; 216:698–703. https://doi.org/10.1148/radiology.216.3. r00se24698 PMID: 10966697

4. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018; 391:1301–14. https://doi.org/10.1016/s0140-6736(18)30010-2 PMID: 29307467

5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359:378–90. https://doi.org/10.1056/NEJMoa0708857 PMID: 18650514

6. Sohn W, Paik YH, Cho JY, Lim HY, Ahn JM, Sinn DH, et al. Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors. J Hepatol. 2015; 62:1112–21. https://doi.org/10.1016/j.jhep.2014.12.009 PMID: 25514557

7. Cheng AL, Guan Z, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. Eur J Cancer. 2012; 48:1452–65. https://doi.org/10.1016/j.ejca.2011.12.006 PMID: 22240282

8. Uka K, Aikata H, Takaki S, Shirakawa H, Jeong SC, Yamashina K, et al. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol. 2007; 13:414–20. https://doi.org/10.3748/wjg.v13.i3.414 PMID: 17230611

9. Lee HS. Management of patients with hepatocellular carcinoma and extrahepatic metastasis. Dig Dis. 2011; 29:333–8. https://doi.org/10.1159/000327572 PMID: 21829026

10. Lee HW, Sinn DH, Kang W, Gwak GY, Paik YH, Choi MS, et al. Cause of Mortality for Hepatocellular Carcinoma Patients who were Diagnosed within the Milan Criteria. J Liver Cancer. 2016; 16:101–7. https://doi.org/10.17998/jl.jc.2016.16.2.101

11. Uchino K, Tateishi R, Shinia S, Kanda M, Masuzaki R, Kondo Y, et al. Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer. 2011; 117:4475–83. https://doi.org/10.1001/caner.2011.25960 PMID: 21437884

12. Sinn DH, Cho JY, Gwak GY, Paik YH, Choi MS, Lee JH, et al. Different survival of Barcelona clinic liver cancer stage C hepatocellular carcinoma patients by the extent of portal vein invasion and the type of extrahepatic spread. PLoS One. 2015; 10:e0124434. https://doi.org/10.1371/journal.pone.0124434 PMID: 25923439

13. Kim KM, Sinn DH, Jung SH, Gwak GY, Paik YH, Choi MS, et al. The recommended treatment algorithm of the BCLC and HKLC staging systems: does following these always improve survival rates for HCC patients? Liver Int. 2016; 36:1490–7. https://doi.org/10.1111/liv.13107 PMID: 26936471

14. Yoo DJ, Kim KM, Jin YJ, Shim JH, Ko GY, Yoon HK, et al. Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: does transarterial chemoembolization improve survival in these patients? J Gastroenterol Hepatol. 2011; 26:145–54. https://doi.org/10.1111/j.1440-1746.2010.06341.x PMID: 21175808

15. Bettinger D, Spode R, Glaser N, Böttner T, Neumann-Haefelin C, et al. Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience. BMC Gastroenterol. 2017; 17:98. https://doi.org/10.1186/s12876-017-0656-z PMID: 28797231

16. [Practice guidelines for management of hepatocellular carcinoma 2009]. Korean J Hepatol. 2009; 15:391–423. https://doi.org/10.3350/kjhep.2009.15.3.391 PMID: 19783891

17. 2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma. Gut Liver. 2015; 9:267–317. https://doi.org/10.5009/gnl14460 PMID: 25918260

18. Hyun D, Cho SK, Shin SW, Rhim H, Koh KC, Paik SW. Treatment of Small Hepatocellular Carcinoma (<1 = 2 cm) in the Caudate Lobe with Sequential Transcatheter Arterial Chemoembolization and Radiofrequency Ablation. Cardiovasc Intervent Radiol. 2016; 39:1015–22. https://doi.org/10.1007/s00270-016-1314-5 PMID: 26975761

19. Jang JY, Lee JS, Kim HJ, Shim JJ, Kim JH, Kim BH, et al. The General Rules for the Study of Primary Liver Cancer. J Liver Cancer. 2017; 17:19–44. https://doi.org/10.17998/jlc.17.1.19

20. Jung SM, Jang JW, You CR, Yoo SH, Kwon JH, Bae SH, et al. Role of intrahepatic tumor control in the prognosis of patients with hepatocellular carcinoma and extrahepatic metastases. J Gastroenterol Hepatol. 2012; 27:684–92. https://doi.org/10.1111/j.1440-1746.2011.06917.x PMID: 21916984

21. Kirstein MM, Voigtlander T, Schweitzer N, Hinrichs JB, Marquardt J, Wörsn M-A, et al. Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic...
22. Yoo JJ, Lee JH, Lee SH, Lee M, Lee DH, Cho Y, et al. Comparison of the effects of transarterial chemoembolization for advanced hepatocellular carcinoma between patients with and without extrahepatic metastases. PLoS One. 2014; 9:e113926. https://doi.org/10.1371/journal.pone.0113926 PMID: 25427152

23. Pinter M, Hucke F, Graziaidi I, Vogel W, Maieron A, Königsberg R, et al. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiology. 2012; 263:590–9. https://doi.org/10.1148/radiol.12111550 PMID: 22438359

24. Nishikawa H, Osaki Y, Iguchi E, Takeda H, Nakajima J, Matsuda F, et al. Comparison of the efficacy of transcatheter arterial chemoembolization and sorafenib for advanced hepatocellular carcinoma. Exp Ther Med. 2012; 4:381–6. https://doi.org/10.3892/etm.2012.611 PMID: 23181103

25. Choi GH, Shim JH, Kim MJ, Ryu MH, Ryoo BY, Kang YK, et al. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. Radiology. 2013; 269:603–11. https://doi.org/10.1148/radiol.13130150 PMID: 23864102

26. Qu XD, Chen CS, Wang JH, Yan ZP, Chen JM, Gong GQ, et al. The efficacy of TACE combined sorafenib in advanced stages hepatocellular carcinoma. BMC Cancer. 2012; 12:263. https://doi.org/10.1186/1471-2407-12-263 PMID: 22721173

27. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018; 69:182–236. https://doi.org/10.1016/j.jhep.2018.03.019 PMID: 29628281

28. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985; 56:918–28. PMID: 2990661

29. Cabibbo G, Enea M, Attanasio M, Bruix J, Craxi A, Camma C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology. 2010; 51:1274–83. https://doi.org/10.1002/hep.23485 PMID: 20112254

30. Hiraoka A, Kumada T, Kudo M, Hirooka M, Koizumi Y, Hiasa Y, et al. Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis. Dig Dis. 2017; 35:602–10. https://doi.org/10.1159/000480256 PMID: 29040999

31. Yoon SM, Ryoo BY, Lee SJ, Kim JH, Shin JH, An JH, et al. Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial. JAMA Oncol. 2018; 4:661–9. https://doi.org/10.1001/jamaoncol.2017.5847 PMID: 29543938